**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Dipan Uppal, Cleveland Clinic Florida, Weston, FL

**Main Body of the Abstract**
Background: Cardiac amyloidosis (CA) involves abnormal amyloid protein deposition in organs, including the heart, causing restrictive cardiomyopathy. Atrial fibrillation (AF) prevalence in CA patients is higher than in age-matched populations. AF, the most common sustained arrhythmia globally, poses higher risks of stroke, cognitive impairment, myocardial infarction, sudden cardiac death, heart failure, chronic kidney disease, and peripheral artery disease. AF, poorly tolerated in CA due to restricted ventricular filling, shows a male preponderance. Limited data exists on gender differences in AF incidence among CA patients.
Methods: We conducted a single-center retrospective cohort study involving patients with ATTR-CA evaluated between 02/2016 and 12/2022. We compared patient demographics, comorbidities and AF burden across genders.
Results: Our registry comprised 214 patients, with AF noted in 73% (n=156) at diagnosis, significantly higher than the general population over 80 years (9%). Males constituted 91% (n=195) and females 9% (n=19). Despite a lower mean age of females (79.6 years vs. 81.2 years), there was no statistically significant difference in AF prevalence between genders after adjustment for co-morbidities, including age, race, CAD, prior CABG, COPD, DM, HTN, CKD (p value 0.21).
Conclusions: AF is the most common arrhythmia in general population, with a prevalence as high as 9% among individuals above the age of 80 years. Our data showed that the prevalence was much higher (73%) in patients with ATTR-CA. Although, males typically have higher prevalence of AF, our data indicates no statistical gender disparity, highlighting elevated risk among females with ATTR-CA.



Atrial Fibrillation Prevalence and Gender Disparities in Patients with Transthyretin Cardiac Amyloidosis: Insights from a Retrospective Cohort Study PB74 (#258) 

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.